Deficiency of M2 muscarinic acetylcholine receptors increases susceptibility of ventricular function to chronic adrenergic stress

Am J Physiol Heart Circ Physiol. 2008 Feb;294(2):H810-20. doi: 10.1152/ajpheart.00724.2007. Epub 2007 Nov 30.

Abstract

Suppressed parasympathetic nervous system (PSNS) function has been found in a variety of cardiovascular diseases, such as hypertension, heart failure, and diabetes. However, whether impaired PSNS function plays a significant role in ventricular dysfunction remains to be investigated. Cardiac regulation by the PSNS is primarily mediated by the M(2) muscarinic acetylcholine receptor (M(2)-AChR). In this study, we tested the hypothesis that lack of M(2)-AChR-mediated PSNS function may adversely impact cardiac ventricular function. Using M(2)-AChR knockout (KO) and wild-type (WT) mice, we found that the basal levels of heart rate and left ventricular function were similar in M(2)-AChR KO and WT mice. A bolus injection of isoproterenol (Iso) induced a greater increase in heart rate in M(2)-AChR KO mice than in WT mice. However, the responses of change in pressure over time (dP/dt) to Iso were similar in the two groups. After chronic infusion with Iso for 1 wk, the baseline values of left ventricular function were increased to similar extents in M(2)-AChR KO and WT mice. However, the M(2)-AChR KO mice exhibited impaired ventricular function, indicated as attenuated dP/dt and increased end-diastolic pressure, during an increase in cardiac afterload induced by a bolus injection of phenylephrine. Furthermore, chronic Iso infusion significantly increased matrix metalloproteinase (MMP) activity in the heart in M(2)-AChR KO mice. In primary culture of mixed neonatal rat cardiac fibroblast and cardiomyocytes, cotreatment with muscarinic agonist bethanechol reversed phenylephrine-induced increase in MMP-9 activation. These data suggest that M(2)-AChR may mediate an inhibitory regulation on MMP function. The overall results from this study suggest that M(2)-AChR-mediated PSNS function may provide cardiac protection. Lack of this protective mechanism will increase the susceptibility of the heart to cardiac stresses.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Agonists / pharmacology
  • Animals
  • Blood Pressure / drug effects
  • Blotting, Western
  • Cells, Cultured
  • Chronic Disease
  • Heart / physiopathology*
  • Heart Rate / physiology
  • Heart Ventricles
  • Isoproterenol / pharmacology
  • Matrix Metalloproteinases / metabolism
  • Mice
  • Mice, Knockout
  • Mitogen-Activated Protein Kinases / metabolism
  • Muscarinic Agonists / pharmacology
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / physiology
  • Phenylephrine / pharmacology
  • Phosphorylation
  • RNA / biosynthesis
  • RNA / genetics
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Muscarinic M2 / genetics
  • Receptor, Muscarinic M2 / physiology*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Stress, Physiological / physiopathology*
  • Sympathetic Nervous System / physiopathology*
  • Tissue Inhibitor of Metalloproteinases / biosynthesis
  • Tissue Inhibitor of Metalloproteinases / genetics
  • Vasoconstrictor Agents / pharmacology
  • Ventricular Function, Left / physiology

Substances

  • Adrenergic beta-Agonists
  • Muscarinic Agonists
  • Receptor, Muscarinic M2
  • Tissue Inhibitor of Metalloproteinases
  • Vasoconstrictor Agents
  • Phenylephrine
  • RNA
  • Mitogen-Activated Protein Kinases
  • Matrix Metalloproteinases
  • Isoproterenol